Insider Trading Activity Cara Therapeutics, Inc. (NASDAQ:CARA) – VP Sold 3,000 shares of Stock

ME Staff

7 years ago

Insider Trading Activity For Cara Therapeutics, Inc. (NASDAQ:CARA)

Frederique Ph.D. Menzaghi , VP of Cara Therapeutics, Inc. (NASDAQ:CARA) reportedly Sold 3,000 shares of the company’s stock at an average price of 15 for a total transaction amount of $45,000.00 SEC Form

Insider Trading History For Cara Therapeutics, Inc. (NASDAQ:CARA)

On 2/5/2014 Ventures Vi Lp Rho, Major Shareholder, bought 225,818 with an average share price of $11.00 per share and the total transaction amounting to $2,483,998.00.View SEC Filing

On 2/2/2015 Michael E Lewis, Insider, sold 7,262 with an average share price of $10.60 per share and the total transaction amounting to $76,977.20.View SEC Filing

On 3/2/2015 Michael E Lewis, Insider, sold 7,262 with an average share price of $10.11 per share and the total transaction amounting to $73,418.82.View SEC Filing

On 4/1/2015 Michael E Lewis, Insider, sold 7,262 with an average share price of $9.90 per share and the total transaction amounting to $71,893.80.View SEC Filing

On 5/19/2015 Dean Slagel, Director, sold 188,811 with an average share price of $10.02 per share and the total transaction amounting to $1,891,886.22.View SEC Filing

On 6/1/2015 Michael E Lewis, Insider, sold 7,262 with an average share price of $9.50 per share and the total transaction amounting to $68,989.00.View SEC Filing

On 8/18/2015 Josef Schoell, CFO, bought 3,000 with an average share price of $22.10 per share and the total transaction amounting to $66,300.00.View SEC Filing

Analyst Ratings For Cara Therapeutics, Inc. (NASDAQ:CARA)
These are 2 Hold Ratings, 9 Buy Ratings .
The current consensus rating for Cara Therapeutics, Inc. (NASDAQ:CARA) is Buy (Score: 2.82) with a consensus target price of $27.25 , a potential (79.87% upside)

Analyst Ratings History For Cara Therapeutics, Inc. (NASDAQ:CARA)

On 5/15/2017 Raymond James Financial, Inc. Lower Price Target of rating Market Perform with a price target of $30.00 to $28.00
On 5/15/2017 Royal Bank Of Canada Lower Price Target of rating Outperform with a price target of $32.00 to $31.00
On 5/15/2017 Scotiabank Boost Price Target of rating Outperform with a price target of $33.00 to $34.00
On 5/19/2017 Cantor Fitzgerald Reiterated Rating Overweight with a price target of $29.00
On 6/30/2017 Janney Montgomery Scott Downgraded rating Buy to Neutral with a price target of $22.00 to $21.00
On 6/30/2017 Stifel Nicolaus Reiterated Rating Buy to Buy with a price target of $24.00 to $20.00

Recent Trading Activity for Cara Therapeutics, Inc. (NASDAQ:CARA)
Shares of Cara Therapeutics, Inc. closed the previous trading session at 15.15 down -0.28 -1.81% with 1,681,021 shares trading hands.